Elsevier

International Journal of Cardiology

Volume 209, 15 April 2016, Pages 153-160
International Journal of Cardiology

Real-world cost effectiveness of MitraClip combined with Medical Therapy Versus Medical therapy alone in patients with moderate or severe mitral regurgitation

https://doi.org/10.1016/j.ijcard.2016.01.212Get rights and content

Abstract

Background

We evaluated the real-world cost-effectiveness of the MitraClip system (Abbott Vascular Inc., Menlo Park, CA) plus medical therapy for patients with moderate/severe mitral regurgitation, as compared with medical therapy (MT) alone.

Methods

Clinical records of patients with moderate to severe functional mitral regurgitation treated with MitraClip (N = 232) or with MT (N = 151) were collected and outcome analyzed with propensity score adjustment to reduce selection bias. Twelve-month outcomes were modeled over a lifetime horizon to conduct a cost-effectiveness analysis, in the payer's perspective. Costs and benefits were discounted at an annual rate of 3.5%.

Results

After propensity score adjustment, the average treatment effect was − 9.5% probability of dying at 12 months and, following lifetime modeling, 3.35 ± 0.75 incremental life years and 3.01 ± 0.57 incremental quality-adjusted life years. MitraClip contributed to a higher decrease in re-hospitalizations at 12 months (difference =  0.54 ± 0.08) and generated a more likely improvement in the New York Heart Association (NYHA) class at 12 months versus NYHA at enrollment. Incremental costs, adapted to five possible scenarios, ranged from 14,493 to 29,795 € contributing to an incremental cost-effectiveness ratio ranging from 4796 to 7908 €.

Conclusions

Compared to MT alone and given conventional threshold values, MitraClip can be considered a cost-effective procedure. The cost-effectiveness of MitraClip is in line or superior to the one of other non-pharmaceutical strategies for heart failure.

Introduction

The relative burden of mitral valve diseases is often underestimated [1]. Untreated mitral regurgitation (MR) may lead to deterioration of left ventricular function, poor prognosis and adverse clinical events. The advent of less invasive techniques is providing potential new opportunities for patients previously not treated or at high surgical risk [2]. MitraClip (Abbott Vascular Inc. Menlo Park, CA) has been launched into the market in 2008. Before and after its introduction, several international studies and trials have evaluated the effectiveness of the MitraClip procedure [3], [4], [5], [6], [7], [8], [9], [10], [11], [12], [13], [14]. In its early uptake, MitraClip has been used both for functional and degenerative MR [15]. A large European registry provided some evidence of MitraClip effectiveness, with relatively few events and low mortality rates in high-risk, elderly patients, mainly affected by functional MR [16].

Economic evaluations of medical devices pose several challenges [17], [18] that sometimes make randomized trials difficult and eventually unethical if there is sufficient agreement on a new treatment's higher effectiveness. Observational studies are recognized as a valuable source of evidence when evidence from randomized clinical trials is scarce, being capable of timely informing regional and national policies on one side and to support evidence-based technologies' adoption on the other side, with remarkable impacts on medical device companies [17]. At present, the most appropriate comparator to evaluate MitraClip cost-effectiveness in patients with MR and severe heart failure may not be the traditional surgical intervention, since most patients receiving the implant in contemporary practice would not be ideal surgical candidates.

On the background of the available evidence and to address the economic evaluation challenges in the treatment for MR, the present study aimed at assessing the cost-effectiveness of MitraClip combined with medical therapy versus medical therapy alone in patients with moderate/severe MR and severe heart failure. Secondary objectives were to identify the impact of MitraClip treatment on different dimensions of effectiveness (i.e., consumption of drugs and hospitalizations) and to compare relevant cost items across treatment groups in the payer's perspective.

Section snippets

Study datasets

This is a retrospective, nonrandomized, and observational study of patients with heart failure. We used data from 383 patients with heart failure and moderate/severe functional MR (232 consecutive patients treated with MitraClip plus medical therapy [MC group] treated between 2008 and 2012, and a control group of 151 randomly selected patients treated with medical therapy only [MT group] treated between 2007 and 2009, Table 1). Medical therapy was defined as the use of guideline-recommended

Baseline characteristics and medications

Table 1 reports baseline characteristics of the MC and MT groups before adjustment for potential confounders. Age and gender were distributed similarly in the two groups. NYHA at enrollment was significantly higher in the MC group while the number of hospitalizations in the previous year was lower. Other significant differences were the prevalence of previous revascularization, previous pacemaker implantation, dyslipidemia, and hypertension, all higher in the MC group, and creatinine at

Discussion

Technological innovation is evolving at a higher pace than economic growth. This represents a challenge for decision-makers who struggle between scarcity of resources and access to innovations. Cost-effectiveness analysis represents a viable approach to estimate the incremental benefit for the unit of cost thus advising resource allocation. Source of clinical evidence is more challenging for devices than for drugs with the first showing true effectiveness when already adopted in clinical

Conflict of interest

Davide Capodanno, Carmelo Grasso, Corrado Tamburino and Francesco Maisano report speakers' honoraria from Abbott Vascular. Aldo Pietro Maggioni is a member of the Executive Committee of a trial sponsored by Abbott Vascular. All the other authors have no conflict of interest to disclose.

Acknowledgments

The study was conducted thanks to an unrestricted grant from Abbott Vascular and developed at CERGAS Bocconi. The authors thank the two hospitals involved in the study, San Raffaele Hospital in Milan and Ferrarotto Hospital in Catania, and the Italian Association of Hospital Cardiologists (ANMCO), all clinicians and medical staff. They also thank Aureliano Paolo Finch for the relevant suggestions provided on statistical analysis methods.

References (29)

  • M. Drummond et al.

    Economic evaluation for devices and drugs—same or different?

    Value Health

    (2009)
  • G. Cioffi et al.

    Clinical features, and in-hospital and 1-year mortalities of patients with acute heart failure and severe renal dysfunction. data from the Italian registry IN-HF outcome

    Int. J. Cardiol.

    (2013)
  • G.P. Ussia et al.

    Quality of life following percutaneous mitral valve repair with the MitraClip system

    Int. J. Cardiol.

    (2012)
  • T. Feldman et al.

    Patient selection for percutaneous mitral valve repair: insight from early clinical trial applications

    Nat. Clin. Pract. Cardiovasc. Med.

    (2008)
  • Cited by (40)

    • Left Ventricular Size Predicts Clinical Benefit After Percutaneous Mitral Valve Repair for Secondary Mitral Regurgitation: A Systematic Review and Meta-Regression Analysis

      2020, Cardiovascular Revascularization Medicine
      Citation Excerpt :

      The subgroup analysis of patients with secondary MR enrolled in the EVEREST II trial [5] reported similar outcome for surgery and PMVR. Several nROS [7–13] supported the widespread use of MitraClip, showing promising clinical results in unselected populations. However, long-awaited results from 2 RCTs [16,17] directly comparing PMVR+OMT vs OMT in patients with secondary MR reported controversial findings.

    • Valuing surgical technology

      2020, Surgery (United States)
    • Percutaneous Mitral Valve Repair Vs. Stand-Alone Medical Therapy in Patients with Functional Mitral Regurgitation and Heart Failure

      2020, Cardiovascular Revascularization Medicine
      Citation Excerpt :

      Thirteen reports were deeply evaluated for eligibility. Ultimately, five studies, two RCT [6,7] and three observational [12–14] series satisfied all inclusion criteria and were used in the qualitative appraisal and quantitative data extraction. Overall, 1513 patients were included.

    • Is the MitraClip® procedure profitable in a high-volume French hospital?

      2019, Archives of Cardiovascular Diseases
      Citation Excerpt :

      The MitraClip® procedure is expensive, and device implantation in elderly patients with co-morbidities is questionable for the society and the hospital. Yet, several cost-effectiveness studies based on extrapolation models suggest that the MitraClip® procedure is cost-effective over time compared with conventional medical management in patients with severe MR [12–15]. In France, the French National Health Service has refunded the MitraClip® device since November 2016 for degenerative MR, in symptomatic patients who are not eligible for surgical repair after Heart Team evaluation.

    View all citing articles on Scopus
    View full text